Amylin Pharmaceuticals Acquires Facility in Ohio to Manufacture Exenatide LAR
Facility and process design efforts are already underway and construction is set to begin in early 2006. The facility is expected to cost up to $150 million and will be completed in phases, allowing initial use of the facility before final aspects of construction are completed in 2008.
Amylin's new facility is being designed to manufacture exenatide LAR in bulk form and finished drug product, and will also include packaging capabilities. The commercial use of this facility will depend upon successful clinical development, manufacturing scale up activities, validation and regulatory approval. The plans for the facility also include manufacturing of exenatide LAR for clinical studies at increasing scale prior to transitioning to commercial manufacturing. Alkermes, Inc. will continue to provide exenatide LAR for clinical studies.
Most read news
Other news from the department manufacturing
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.